AE, adverse event

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 889-894; DOI: 10.1136/ard.2005.043166
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R Burmester, Xavier Mariette, Carlomaurizio Montecucco, Indalecio Monteagudo-Sáez, Michel Malaise, Athanasios G Tzioufas, Johannes W J Bijlsma, Kristina Unnebrink, Sonja Kary, Hartmut Kupper

Annals of the Rheumatic Diseases Jun 2007, 66 (6) 732-739; DOI: 10.1136/ard.2006.066761
The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip
F Boureau, H Schneid, N Zeghari, R Wall, P Bourgeois

Annals of the Rheumatic Diseases Sep 2004, 63 (9) 1028-1034; DOI: 10.1136/ard.2003.011403
Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis
Federico Díaz-González, Rieke H E Alten, William G Bensen, Jacques P Brown, John T Sibley, Maxime Dougados, Stefano Bombardieri, Patrick Durez, Pablo Ortiz, Gonzalo de-Miquel, Alexander Staab, Ralf Sigmund, Laurence Salin, Caroline Leledy, Stephen H Polmar

Annals of the Rheumatic Diseases May 2007, 66 (5) 628-632; DOI: 10.1136/ard.2006.062554
Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study
Bernard Mazières, Michel Hucher, Mohammed Zaïm, Patrick Garnero

Annals of the Rheumatic Diseases May 2007, 66 (5) 639-645; DOI: 10.1136/ard.2006.059899

Log in using your username and password

Main menu

Log in using your username and password

You are here

AE, adverse event